Consumer Health

Consumer health is set to maintain solid current value growth in 2023, with increases across most categories. Analgesics, and cough, cold and allergy (hey fever) remedies are expected to remain the largest OTC categories. Due to their maturity and…

Retail volume sales of some consumer health products in 2023 are declining following a surge in demand the previous year when pandemic-related restrictions in April 2022 resulted in Spaniards returning to some extent to their pre-pandemic lives. This…

In 2023, Tanzania faces high inflation and living costs, causing consumers to favour lower-priced generic medications over pricey international brands. Essential categories, such as analgesics, cough, cold, allergy remedies, and digestive remedies,…

In 2022, consumer health in the Czech Republic was challenged by medicine shortages, which, to some degree, continued in Q1 2023. The lack of some medicines in the Czech Republic and throughout Europe was caused by the disruption of global supply…

Combination drugs are often used to treat multiple symptoms or conditions with a single medication. They can be very helpful in simplifying medication regimens and improving patient adherence. Combination drugs are also beneficial in a number of…

Whilst the category continues to record growth in 2023, the particularly high growth level seen in the previous year could not be maintained. 2022 was a strong year for the category as consumers returned to their pre-pandemic lifestyles following the…

Cough, cold and allergy (hay fever) sales are expected to be slightly down in 2023. This is partly a result of the very strong performance seen in the previous year, as the lifting of COVID-19 related restrictions led to greater social contact and…

The majority of subcategories within cough, cold and allergy remedies recorded positive growth in retail volume terms in 2023. This was due, in a large part, to a return pre-pandemic lifestyles, which facilitated the spread of the influenza virus and…

During the winters 2020/2021 and 2021/2022, the circulation of cough, cold and flu viruses was limited by the restrictions implemented to contain the COVID-19 pandemic. Winter 2022/2023 was the first one with no restrictions in place at all and this…

Following the return to normality in the wake of the COVID-19 crisis, with no more lockdowns or movement restrictions, there has been an increase in the spread of cold and flu viruses, as well as a widespread rise in issues caused by hay fever and…

The pandemic has led consumers to become more concerned about the products they consume, and more conscious of side-effects, with some people therefore preferring to purchase herbal/traditional products instead of standard products, or those needing…

After the surge in sales that cough, cold and allergy (hay fever) remedies experienced in 2022, demand is waning in 2023, with the category recording more subdued growth rates. Traditionally, sales of cough, cold and allergy (hay fever) remedies in…

In 2022, cough, cold and allergy (hay fever) remedies was marked by increases in demand for products to soothe sore throat and cough complaints. This development was a result of extremely high morbidity throughout the year. In the first half of 2022,…

Affordability is a key factor within dermatologicals, with some products on the landscape being very expensive for the average consumer. As such, people need to find products within their budget, allowing them to address their specific skin issues.…

Sales of dermatologicals have benefited from the return to normal activities following the lifting of pandemic-related restrictions. Consumers are out in public again and socialising and are consequently looking to treat any conditions to ensure thy…

Healthy growth in dermatologicals is stemming from launches of value-added products. There was a pause on most new product development activity during the COVID-19 crisis, but with the end of the pandemic, products that had been held back have been…

Most types of dermatologicals saw an upward sales trend in retail volume terms in 2023, although the rate of expansion was lower than that seen in many other consumer health categories. Despite the increasing incidence of diagnosed skin diseases…

Dermatologicals is set to register positive growth in current value and retail volume terms in 2023. With the WHO declaring the pandemic to be over in May 2023, there has been an increase in socialisation and physical contact between people which has…

International players with broad portfolios continue to lead the way in dermatologicals, with Bayer Romania the top-ranked company. Bayer Romania’s Canesten, the best-selling product in both topical and vaginal antifungals, is expected to maintain…

In 2023, dermatologicals is set to return to solid current value growth, although performances are expected to vary widely across categories. For instance, hair loss treatments is expected to continue to benefit from consumers’ perception of their…